Adjuvant Radiotherapy in pT1 ‐ 2N0M0 Head and Neck Adenoid Cystic Carcinoma
The Laryngoscope · 2025
DOI: 10.1002/lary.32156 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Laryngoscope, 2025. Verfasst von Praneet C Kaki und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, USA. Hauptthemen laut MEDLINE: Carcinoma, Adenoid Cystic, Head and Neck Neoplasms. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Evidence regarding the indications and survival benefit of adjuvant radiotherapy (aRT) in pT1‐2N0M0 head and neck adenoid cystic carcinoma (HNAdCC) is inconclusive. Lower‐staged, node‐negative HNAdCC therefore represents a rare, moderate‐risk disease category with high variation in adjuvant management depending on patient and physician preferences. Our study investigates the impact of aRT on overall survival (OS) in this rare, moderate‐risk disease category.
Methods
The 2006 to 2018 National Cancer Database was retrospectively reviewed for patients with pT1‐2N0M0 HNAdCC. Multivariable binary logistic and Cox regression models were implemented.
Results
Of 738 patients satisfying inclusion criteria, 379 (51.4%) underwent aRT. Oral cavity primary site (aOR 0.64, 95% CI 0.43–0.96) was associated with lower odds of undergoing aRT ( p < 0.05); neck dissection (aOR 1.58, 95% CI 1.09–2.28) and PSM (aOR 1.84, 95% CI 1.30–2.60) were associated with higher odds of undergoing aRT ( p < 0.025). Patients undergoing aRT had higher 5‐year (94% vs. 86%) and 10‐year OS (85% vs. 73%) than those not undergoing aRT ( p < 0.001). Adjusting for patient demographics, pathologic features, and treatment, age at diagnosis (aHR 1.05, 95% CI 1.02–1.08, p < 0.001) was associated with worse OS; aRT (aHR 0.30, 95% CI 0.13–0.69, p = 0.005) was associated with higher OS.
Conclusion
Approximately half of patients with pT1‐2N0M0 HNAdCC did not undergo aRT, highlighting a possible deviation from evidence‐based recommendations and an opportunity for quality improvement in the multidisciplinary care of patients. aRT was associated with higher 5‐year and 10‐year OS, suggesting that patients with lower‐staged, node‐negative HNAdCC should be offered aRT to optimize long‐term survival. Level of Evidence 4.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otolaryngology-Head and Neck Surgery, Rutgers New Jersey Medical School, Newark, New Jersey, USA.
ORCID-Profile: Praneet C Kaki, Aman M Patel, David W Wassef
Zitieren
APA
Kaki, P. C., Patel, A. M., Haleem, A., Patel, A. R., Bahethi, R., Wassef, D. W., Cowan, P. T., & Park, R. C. W. (2025). Adjuvant Radiotherapy in pT1 ‐ 2N0M0 Head and Neck Adenoid Cystic Carcinoma. The Laryngoscope. https://doi.org/10.1002/lary.32156
Vancouver
Kaki PC, Patel AM, Haleem A, Patel AR, Bahethi R, Wassef DW, et al. Adjuvant Radiotherapy in pT1 ‐ 2N0M0 Head and Neck Adenoid Cystic Carcinoma. The Laryngoscope. 2025. doi:10.1002/lary.32156
BibTeX
@article{Kaki2025,
author = {Kaki, Praneet C and Patel, Aman M and Haleem, Afash and Patel, Akash R and Bahethi, Rohini and Wassef, David W and Cowan, Paul T and Park, Richard Chan Woo},
title = {Adjuvant Radiotherapy in pT1 ‐ 2N0M0 Head and Neck Adenoid Cystic Carcinoma},
journal = {The Laryngoscope},
year = {2025},
doi = {10.1002/lary.32156}
}
EUVIMED